All In Biotech

Investigational drug · Phase 3

HC-1119

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for MCRPC.

Phase 3

Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

6

Any phase or sponsor naming "HC-1119"

First trial start

2019

Apr 12, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HC-1119", any sponsor or status.

Conditions studied

As listed on its trial records.

  • MCRPC

Largest trials

Live from ClinicalTrials.gov: studies naming "HC-1119" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6 on PubMed

Also in development for MCRPC

  • REGN5678NezastomigPhase 23 trials

    Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

  • TYK-00540Phase 22 trials

    TYK Medicines, Inc · mCRPC, HR-positive, HER2-negative Advanced Breast Cancer

  • ZEN003694ZEN-3694Phase 22 trials

    Zenith Epigenetics · mCRPC, Metastatic Castration-Resistant Prostate Cancer

  • Ga-68-NGULPhase 21 trial

    Cellbion Co., Ltd. · Prostate Cancer, mCRPC

  • Lu-177-DGULPhase 21 trial

    Cellbion Co., Ltd. · Prostate Cancer, mCRPC

  • REGN21353Phase 21 trial

    Regeneron · Metastatic Castration-Resistant Prostate Cancer, mCRPC

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.